A Phase 3 interventional study of Semaglutide 1.7mg subcutaneous and Placebo in Obesity/Therapy, sponsored by University of Colorado, Denver. Not yet recruiting at 1 site in United States. Open to participants aged 12 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-07-02.
Sponsored by University of Colorado, Denver · Phase 3, Interventional, and Treatment
Among 143 studies testing semaglutide in Obesity — 68 open to participants now, 77 under way, 14 of them phase 3. Semaglutide · Obesity.
Among the 143 studies testing semaglutide in Obesity, this one is the 58th largest by planned enrollment, is one of 30 that started in 2026, is one of 42 in phase 3, reaches primary completion later than 75 of the 76 other live ones, and was the 101st registered.
11,522 studies on the registry are indexed under Obesity; 2,033 are open to participants now.
This study's planned enrollment of 120 is above the median of 67 across 9,006 interventional studies indexed under Obesity.
Browse Obesity studies →68 of the 143 studies testing semaglutide in Obesity are open now, in 12 countries. Each count lists the studies.
Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 1,336 Obesity studies recruiting now, 377 (28%) set no upper age limit and 856 (64%) stop at 75 or younger; 168 take children under 18; 491 take healthy volunteers.
This study: 12 Years to 45 Years · all sexes · no healthy volunteers.
The full table on the hub →On this site’s reading of the record, semaglutide is the treatment under test here. Read study by study →
143 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 30 started in 2026.
Median enrollment 100 across the 143 interventional studies. Of the 60 that completed or were terminated, 35 (58%) have results posted.
49 of 143 have an industry lead sponsor. The 10 most frequent:
University of Colorado, Denver is the lead sponsor of 1,543 studies on the registry; 317 are open to participants now.
Of its 147 completed or terminated interventional studies of FDA-regulated products, 92 (63%) have results posted.
105 studies in Obesity by University of Colorado, Denver: 19 open now, 32 under way, 2 of them phase 3. Of 68 finished, 27 (40%) have results posted.
Among the 105 studies in Obesity by University of Colorado, Denver, this one is the 16th largest by planned enrollment of the 88 interventional ones, is one of 3 that started in 2026, is one of 3 in phase 3, reaches primary completion later than 30 of the 31 other live ones, and was the 101st registered.
University of Colorado, Denver’s Obesity studies by the year they started, since 2005.
22 of the studies testing semaglutide in Obesity that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07740291Texas Tech UniversityTirzepatide Impact Assessment Study | 2026-11-23 |
| NCT07430059Vivani Medical, IncSafety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide Implant | 2026-12 |
| NCT07225816Novo Nordisk A/SExamination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected) | 2026-12-13 |
| NCT06546384Insel Gruppe AG, University Hospital BernGLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease | 2026-12-31 |
| NCT05173714Srinvasan BeddhuSit Less, Interact and Move More (SLIMM) 2 Study | 2026-12-31 |
Among the 143 studies testing semaglutide in Obesity, from their registry updates:
Among University of Colorado, Denver’s 105 in Obesity:
Glucagon-like peptide 1 receptor agonists (GLP-1RA), such as Ozempic and Wegovy, have been rapidly adopted for the treatment of obesity in both youth and adults. However, despite this rapid adoption and the known GLP-1RA mechanism of action for weight loss, which targets brain circuits responsible for appetite and eating behaviors, almost nothing is known about how these drugs affect the brain in youth who are treated for obesity, or how these drugs affect the brain of youth differently from adults. The goal of the current study is to compare youth and adults with obesity who are treated a GLP-1RA and measure potential difference in GLP-1RA associated change in brain function, appetite, and eating behaviors.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pubertal adolescents defined as Tanner stage 2-4 and/or 12-15 y/o who will receive 32 weeks of semaglutide (s.c.)
Drug: Semaglutide 1.7mg subcutaneous
Pubertal adolescents defined as Tanner stage 2-4 and/or 12-15 y/o who will receive 24 weeks of semaglutide (s.c.) followed by 8 weeks of placebo
Drug: Semaglutide 1.7mg subcutaneous · Drug: Placebo
Post-pubertal adolescents defined as Tanner stage 5 and/or 16-18 y/o who will receive 32 weeks of semaglutide (s.c.)
Drug: Semaglutide 1.7mg subcutaneous
Post-pubertal adolescents defined as Tanner stage 5 and/or 16-18 y/o who will receive 24 weeks of semaglutide (s.c.) followed by 8 weeks of placebo
Drug: Semaglutide 1.7mg subcutaneous · Drug: Placebo
Adults defined as 30-45 y/o who will receive 32 weeks of semaglutide (s.c.)
Drug: Semaglutide 1.7mg subcutaneous
Adults defined as 30-45 y/o who will receive 24 weeks of semaglutide (s.c.) followed by 8 weeks of placebo
Drug: Semaglutide 1.7mg subcutaneous · Drug: Placebo
Semaglutide subcutaneous max dose of 1.7mg over 24 or 32 weeks of active treatment
Also known as: SEMA
Placebo saline solution subcutaneous
blood oxygen-level dependent signal
measured via resting-state functional magnetic resonance imaging
Time frame: From enrollment to the end of trial at 32 weeks
meal kilocalories (kcal)
Measured as kcal consumed from standardized ad libitum meal
Time frame: From enrollment to the end of trial at 32 weeks
visual analogue scale (VAS) score for hunger
pre- and post-meal hunger measured on a 100mm VAS
Time frame: From enrollment to the end of trial at 32 weeks
visual analogue scale (VAS) for desire to eat
pre- and post-meal desire to eat measured on a 100mm VAS
Time frame: From enrollment to end of trial at 32 weeks
visual analogue scale (VAS) score for fullness
pre- and post-meal feeling of fullness measured on a 100mm VAS
Time frame: From enrollment to end of trial at 32 weeks
visual analogue scale (VAS) score for amount participant feels they can eat
pre- and post-meal of amount participant feels they can eat measured on a 100mm VAS
Time frame: From enrollment to end of trial at 32 weeks
Plan to share: No — Pending consent authorization by participants
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Semaglutide
University of Colorado, Denver →